tickerreport.com
Neutralwww.tickerreport.com ·
geron nasdaqgern announces quarterly earnings results beats estimates by 0 02 eps
TAX_FNCACT_CANDIDATETAX_ECON_PRICETAX_DISEASE_CANCERWB_1431_CANCER
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedGeron is a biotech firm focused on telomerase inhibitor imetelstat for hematologic malignancies. The earnings beat and revenue growth are positive but the stock decline suggests market skepticism. The IMpactMF trial interim results are a key catalyst. No direct commodity or supply chain impact; commercial mechanism is weak and company-specific.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Geron Q1 2026 EPS ($0.01) beat estimates by $0.02.
- Q1 net revenue $61.8M, up 31% YoY.
- 2026 revenue guidance $220–$240M.
- Phase III IMpactMF trial fully enrolled, interim results H2 2026.
- Stock fell 4.2% to $1.58, market cap $1.01B.